Title : Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.

Pub. Date : 2020 Sep

PMID : 32814829






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Receptor tyrosine kinase (RTK) inhibitors such as sunitinib have been demonstrated to target tumorigenic signaling pathways, delay tumor progression, and improve patient prognosis in metastatic renal cell carcinoma (mRCC). Sunitinib ret proto-oncogene Homo sapiens
2 Receptor tyrosine kinase (RTK) inhibitors such as sunitinib have been demonstrated to target tumorigenic signaling pathways, delay tumor progression, and improve patient prognosis in metastatic renal cell carcinoma (mRCC). Sunitinib ret proto-oncogene Homo sapiens